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in either the bone marrow (IL-2 1.28%, IL-7 5.97%) or spleen
(IL-2 0.4%, IL-7 0.33%). One experiment was performed with
puriﬁed CD8 positive cells from IL-15 CTL with BM leukemia of
0.037% (P  .01) demonstrating a role for CD8 positive T cells in
the GVL effect. In the second group (hi engraftment) mice not
receiving CTL had a baseline BM leukemia burden of 10.0% (n 
17), and no CTL treatment group had statistical differences: IL-15
11.5% (n  14), IL-2 9.1% (n  7), and IL-7 7.0% (n  5).
Further experiments in the high engraftment model compared PBS
vs IL-2 (20,000 IU) injected IP every 12 hrs for 6 doses. Control
IL-2 injection had no effect on BM leukemia (8.4%, n  10) nor
did IL-15 CTL IL-2 IP (10.3%, n 5) while IL-2 CTL IL-2
IP was statistically lower ( 0.58%, n  6, P  .02). In conclusion
allogeneic CTL grown with IL-15 exerted IL-2 independent GVL
effects on a low leukemia burden while those grown with IL-2
exerted IL-2 dependent GVL effects on a higher leukemia burden,
and this model should be helpful for understanding GVL mecha-
nisms.
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CHRONIC OR ACUTE? GVHD BEYOND DAY 100
Couriel, D.R., Saliba, R.M., Ghosh, S., de Lima, M., Giralt, S.,
Khouri, I., Andersson, B., Mickler, K., Caldera, Z., Hsu, Y.,
Neumann, J., Hymes, S., Kim, S., Champlin, R. Blood and Marrow
Transplantation, The University of Texas M.D. Anderson Cancer Cen-
ter, Houston, TX.
Objective: To assess the clinical and prognostic implications of
the timing of acute GVHD (aGVHD). Introduction: The syn-
drome of a-GVHD has been deﬁned as GVHD occurring before
day 100 post transplant, although it is clear that it can occur later.
This raises the question of potential historical misclassiﬁcation of
a-GVHD as chronic GVHD (c-GVHD). In this study, we assess
the extent of this misclassiﬁcation, and evaluate risk factors as well
as clinical and prognostic differences between GVHD before (clas-
sic aGVHD) and after day 100 (late aGVHD). Methods: Retro-
spective evaluation of database and records on all matched sibling
transplants (n  128) was performed at UT MDACC between
1/00 and 2/02. Clinical manifestations of all GVHD diagnosed
after day 100 post transplant were reviewed to distinguish between
late a-GVHD and c-GVHD. Results: A total of 67/128 patients
were diagnosed with c-GVHD. Upon review of medical records,
30/67 (45%) were found to be late aGVHD, and the remainder
true cGVHD. Of the 30 patients with late aGVHD 9 had pro-
gressing GVHD through day 100, these were reclassiﬁed as classic
aGVHD. We evaluated risk factors for developing late aGVHD in
patients who were alive by day 100, and had no prior diagnosis of
GVHD. Only a later engraftment (ANC 	500 beyond day 12) was
associated with a higher incidence of late aGVHD, while age, gender,
malignancy, disease status at transplant, type of preparative regimen,
cell type or CD3, 4 or 8 infused did not impact the incidence.
Compared to classic aGVHD, the late group had a signiﬁcantly
higher proportion of grade 2-4 GVHD (85 vs 61%, P  .03) with
similar proportion of grade 3-4 aGVHD (29 vs 27%, P .50). There
was a trend to better response (CR/PR) to ﬁrst line immunosuppres-
sion in patients with late aGVHD (81% vs 63%, P .13). The overall
survival (OS) and non-relapse mortality (NRM) since the diagnosis of
GVHDwere substantially better in patients with late aGVHD (OS 70
vs 29%), P  .01; NRM 16 vs 39%, P  .06). Conclusions: (1) The
current chronological deﬁnition of acute GVHDmay lead to misclas-
siﬁcation of late aGVHD as chronic GVHD. This could have impli-
cations in interpreting the current knowledge and literature on
GVHD. (2) There is a trend to better response to therapy and better
survival in patients developing aGVHD beyond day 100. Thus, tim-
ing of aGVHD may affect its outcome.
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CRITICAL ROLE FOR CCR1:CCL5 (RANTES) RECEPTOR LIGAND INTER-
ACTIONS IN MODULATING ALLOGENEIC T CELL RESPONSES FOLLOW-
ING STEM CELL TRANSPLANTATION
Choi, S.W.1, Hildebrandt, G.C.2, Silva, I.A.1, Olkiewicz, K.M.1,
Chensue, S.W.1, Liu, C.3, Chaudhary, M.N.1, Fisher, J.1, Lane, T.E.4,
Cooke, K.R.1 1. University of Michigan, Ann Arbor, MI; 2. University
of Regensburg, Regensburg, Germany; 3. University of Florida, Gaines-
ville, FL; 4. University of California, Irvine, Irvine, CA.
Acute GVHD and leukemic relapse are the most serious com-
plications of allogeneic (allo) stem cell transplantation (SCT). Re-
cruitment of activated T cells to host target tissues (GVHD) or
sites of leukemic inﬁltration (GVL) is likely mediated by chemo-
kine receptor:ligand interactions. CCR1 is a chemokine receptor
that binds to CC chemokines including RANTES (CCL5) and is
expressed on a variety of cells including T cells, monocytes and
macrophages. Using a well-established murine SCT model
(B63B6D2F1) and mice deﬁcient in CCR1, we examined the
contribution of CCR1 expression on donor cells to allo T cell
responses in vitro and to GVH and GVL effects in vivo. Lethally
(1100 cGy) irradiated B6D2F1 mice received SCT from syngeneic
(syn) (B6D2F1) or allo (B6) CCR1/ or CCR1/ donors. Syn
recipients all survived, whereas animals receiving allo-SCT from
CCR1/ donors developed signiﬁcant GVHD. By contrast, allo-
SCT with CCR1/ donor cells resulted in signiﬁcantly im-
proved survival (92% vs. 50%) and less severe clinical GVHD by
day 35 compared to allo-CCR1/ controls. GVL effects were
assessed by adding 500 P815 tumor cells (H-2d, syn to host) to the
SC inoculum on day 0. Syn recipients all died from tumor inﬁl-
tration by day 15. Although allo-SCT recipients effectively re-
jected their tumor, mice receiving CCR1/ SCT had signiﬁ-
cantly improved leukemia free survival (45% vs. 5%) by day 60
compared to allo controls. At higher tumor doses, signiﬁcant GVL
activity remained in CCR1/ SCT recipients, but the survival
advantage was lost. Surprisingly, allo T cell responses in vivo
revealed that day 7 splenic T cell expansion and serum IFN levels
were signiﬁcantly lower following CCR1/ SCT (P  .01).
Proliferation and IFN secretion were also reduced by 70% when
CCR1/ T cells were stimulated with host antigens in vitro,
whereas CTL activity remained equivalent to CCR1/ cells.
The reduction in proliferation was not secondary to a migration
defect, but was dependent on interactions between CCR1 and
RANTES; antibody neutralization of RANTES reduced prolifer-
ation of CCR1/ T cells in a dose-dependent manner. Finally,
we found that GVHD mortality was also less when RANTES/
mice or chimeric wild type mice reconstituted with RANTES/
BM cells were used as recipients in a second, MHC-disparate SCT
model (P  .05). Collectively these data demonstrate a critical role
for CCR1 in donor T cell responses following SCT that contribute
to both GVHD and GVL.
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A CRITICAL ROLE OF SEMA4D (CD100) IN REDUCING GRAFT-VERSUS-
HOST DISEASE IN A MURINE MAJOR MISMATCH TRANSPLANT
Duran-Struuck, R.1, Rogers, C.1, Clouthier, S.1, Gatza, E.1, Liu, C.2,
Kumanogoh, A.3, Reddy, P.1, Ferrara, J.L.M.1 1. University of Mich-
igan Cancer Center, Ann Arbor, MI; 2. University of Florida College of
Medicine, Gainesville, FL; 3. Osaka University, Osaka, Japan.
Sema4D (CD100) is a 150 kDa transmembrane protein member
of the class IV semaphorin family that has immunomodulatory
functions, and is essential for the activation and differentiation of
antigen speciﬁc T cells. We investigated the effects of CD100
expression on T cells in allotransplantation. In vitro studies showed
that T cells from genetically engineered CD100/ mice ex-
panded ten fold less than B6 wild type (wt) T cells (10800 1229.9
vs. 1600  258 cpm P  .01) in response to BALB/c allogeneic
stimulators. We then evaluated the role of CD100 in vivo utilizing
a well characterized experimental model of graft-versus-host dis-
ease (GvHD) where donor and recipient are mismatched at both
major and minor histocompatibility antigens [B6 (H2b)3BALB/c
(H2 d)]. Recipient BALB/c animals were irradiated with 8 Gy and
transplanted with 5.0  106 million bone marrow (BM) cells from
B6 animals together with 0.5 million T cells from either B6 wild
type (wt) or CD100 / donors. As shown in Table 1, at day 60
after transplant, mice that received CD100 / T cells had sig-
niﬁcantly less clinical GvHD scores and improved survival (P 
.08) compared to allogeneic wt T cells. Recipients of CD100/
T cells also demonstrated signiﬁcantly reduced GvHD pathology
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in the intestine, liver and skin on day 60. All of BMT recipients
showed complete donor engraftment. Examination of T cells in the
spleen on day 14 showed that CD100 / T cells expanded
fourfold less than wild type (P  .01). Together our data show that
Sema4D is a co-stimulatory molecule that modulates T cell allo-
geneic responses both in vitro and in vivo and may represent a
novel target for the prevention of GvHD (Table 1).
Table 1. CD100/ vs Wild Type T Cell Transplant Outcomes
Day post
Transplant
wt T
Cells n
CD100/
T Cells n
P
Value
GvHD clinical
score
60 4.6  0.8 6 1.8  0.2 6 <.02
Survival 60 67% 6 100% 6 .08
Liver pathology 60 17.0  1.5 4 9.0  1.3 4 <.01
Skin pathology 60 1.5  0.2 4 0.8  0.2 4 .02
Intestinal
pathology
60 7.8  0.8 8 4.8  1.0 8 .03
T cell expansion
(106)
14 3.95  0.78 5 0.83  0.16 5 <.01
95% conﬁdence interval.
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EXTRACORPOREAL PHOTOPHERESIS (ECP) STIMULATES THE GENER-
ATION OF REGULATORY T CELLS
Strobl, F.J., Huber, J., Krutsick, A., Campbell, K.A., Peritt, D.
THERAKOS, Inc., Exton, PA.
Extracorporeal photopheresis (ECP) involves the reinfusion of
autologous, apoptotic peripheral blood leukocytes treated ex vivo
with 8-methoxypsoralen (8-MOP) and UVA light. ECP is ap-
proved for the palliative treatment of cutaneous T cell lymphoma.
ECP has also shown promise as a treatment for other immune-
mediated inﬂammatory disorders suggesting a common immuno-
logic pathway may be involved in it’s mechanism of action. Several
investigators including ourselves have recently provided in vivo
evidence to suggest that the delivery of ECP-treated apoptotic cells
modulates immune responses, in part, through the generation of
regulatory T cells. In vitro studies have also demonstrated that
activation of naive T cells in the presence of antigen presenting
cells (APCs) that have previously engulfed ECP-treated apoptotic
cells leads to the generation of a T cell population that can suppress
syngeneic T cell proliferation and function. In this study, we
expand the scope of these original ﬁndings by demonstrating that
co-incubation of naive CD4 T cells with ECP-treated peripheral
blood mononuclear cells also results in the development of a
regulatory T cell phenotype. ECP-mediated generation of regula-
tory T cells is dependent on APCs and can be reversed by the
addition of interleukin-2 (IL-2). These regulatory T cells actively
proliferate in response to concanavalin-A (Con A) but do not
secrete signiﬁcant levels of pro-inﬂammatory cytokines. Transfer
of these regulatory T cells to a secondary MLR reaction results in
the inhibition of syngeneic responder T cell proliferation. Addi-
tional studies are underway to characterize these cells and deter-
mine their suppressive capacity in vivo. Collectively, these results
demonstrate that ECP-treated apoptotic cells are capable of mod-
ulating other immune cells, in part, through the generation of
regulatory T cells. Regulatory T cells have been implicated in the
control of a variety of immune-mediated inﬂammatory diseases. It
is hoped that a better understanding of the mechanism of action
behind ECP will help to deﬁne more efﬁcacious and cost-effective
treatment regimens.
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ROLE FOR ACTIVATED DONOR NK CELLS IN PROTECTION FROM
ACUTE, LETHAL GVHD AND THE PROMOTION OF ENGRAFTMENT IN A
PARENTAL STRAIN3F1-HYBRID MODEL
Ellison, C.A.1,2, Fischer, J.M.M.1, Gartner, J.G.1,3 1. Department of
Pathology, University of Manitoba, Winnipeg, MB, Canada; 2. Mani-
toba Blood and Marrow Transplant Program, CancerCare Manitoba,
Winnipeg, MB, Canada; 3. Department of Immunology, University of
Manitoba, Winnipeg, MB, Canada.
The effects of donor NK cells in allogeneic bone marrow trans-
plantation and the development of GVHD remains controversial.
Using the C57BL/63(C57BL/6  DBA/2)F1-hybrid model of
acute GVHD, we performed experiments in which the donor mice
were stimulated with polyinosinic:polycytidylic acid (poly I:C) be-
fore the grafts were harvested. Poly I:C is a potent activator of NK
cell cytotoxicity and an inducer of interferon production. In some
of these experiments, we also removed the adherent cells from the
graft prior to transplantation. The following four experimental
groups were established: (1) recipients of unmanipulated grafts
from unstimulated donors; (2) recipients of unmanipulated grafts
from poly I:C-stimulated donors; (3) recipients of non-adherent
grafts from unstimulated donors; and (4) recipients of non-adher-
ent grafts from poly I:C-stimulated donors. The only group in
which protection from acute, lethal GVHD was seen was group
(4), in which 75% of the recipients survived until at least day 90
post-induction. Only 50% of the recipients in group (4) survived
when the graft was depleted of DX5 cells using a magnetic cell
sorter. This was also associated with a marked reduction in the
level of engraftment of total donor cells, as well as donor T cells in
the long-term survivors in group (4). Our ﬁndings show that
recipients of grafts from poly I:C-stimulated donors are only pro-
tected when the adherent cells are removed from the graft but the
precise mechanism through which protection is achieved is not
known. They further show that donor DX5 cells are at least partly
responsible for the protection we observed and that these cells
promote engraftment, particularly of T cells. Supported by an
establishment grant to CAE from the CancerCare Manitoba Foun-
dation.
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SKIN EXPLANT MODEL OF HUMAN GVHD: PREDICTION OF CLINICAL
OUTCOME AND CORRELATION WITH BIOLOGICAL RISK FACTORS
Wang, X.-N.1, Collin, M.1, Sviland, L.2, Marshall, S.R.1,
Jackson, G.H.3, Schulz, U.4, Holler, E.4, Karrer, S.5, Greinix, H.6,
Elahi, F.6, Hromadnikova, I.7, Dickinson, A.M.1 1. University of New-
castle upon Tyne, Newcastle upon Tyne, United Kingdom; 2. Haukeland
Hospital, Bergen, Norway; 3. Royal Victoria Inﬁrmary, Newcastle upon
Tyne, United Kingdom; 4. Department of Haematology and Oncology,
University of Regensburg, Regensburg, Germany; 5. Department of
Dermatology, University of Regensburg, Regensburg, Germany; 6. Med-
ical University of Vienna, Vienna, Austria; 7. Charles University,
Prague, Czech Republic.
A human skin explant model has been used to predict the clinical
outcome and to study the immunopathology of human GVHD.
Whether the model gives the same predictive effect for GVHD in
different haematopoietic stem cell transplant (HSCT) settings has
not been assessed. It is also unknown whether the skin explant
result reﬂects the known biological risk factors for clinical GVHD.
In this present study the skin explant model was used to detect
graft-versus-host reactions (GVHR) in vitro for 225 eligible pa-
tient/donor pairs. Predicted skin GVHR grade was correlated with
the outcome of clinical GVHD as well as the HLAmatching status,
gender mismatches and patient age. In sibling HSCT under either
myeloablative or reduced intensity conditioning a signiﬁcant cor-
relation was observed between the predicted skin GVHR and
clinical GVHD (P  .001 and P  .033 respectively). In HSCT
using unrelated donors the involvement of T cell depletion led to
a sharp increase in false positive GVHR results and no correlation
was observed between the predicted skin GVHR and clinical
GVHD. Skin GVHR grade correlated signiﬁcantly with HLA
matching status (HLA matched sibling pairs, HLA matched unre-
lated pairs and HLA unmatched unrelated pairs). Furthermore
HLA matched sibling pairs with female to male gender mismatch
gave rise to signiﬁcantly higher overall skin GVHR grade and
higher ratio of high vs low grade skin GVHR than the sibling pairs
with all other gender combinations. Patient age was not reﬂected
in the skin explant result. In conclusion, the predictive value of the
skin explant model for aGVHD varies depending on the clinical
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